Scientists could soon develop personalized cancer vaccines.

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

Good news has been scarce for this beaten-down drugmaker.

Shares of Oric Pharmaceuticals sank 40% Wednesday after the cancer biotech reported study results that were positive--but not positive enough for Wall Street. In an early-stage trial, Oric’s prostate- ...